Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings results on Thursday. The medical research company reported $0.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.37, reports. Bio-Rad Laboratories had a return on equity of 3.49% and a net margin of 1.15%. The business had revenue of $535.00 million for the quarter, compared to the consensus estimate of $507.99 million. During the same quarter last year, the business posted $0.62 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis.

Bio-Rad Laboratories (NYSE:BIO) traded up $43.56 on Friday, hitting $261.42. The stock had a trading volume of 746,391 shares, compared to its average volume of 153,273. The stock has a market cap of $6.43 billion, a PE ratio of 68.87 and a beta of 0.88.

In other news, EVP Michael Crowley sold 700 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.29% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at

A number of equities research analysts have weighed in on BIO shares. Zacks Investment Research downgraded Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Deutsche Bank AG reiterated a “buy” rating and issued a $255.00 price objective on shares of Bio-Rad Laboratories in a report on Monday, September 18th. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective on the stock. TheStreet downgraded Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, July 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $260.00.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Earnings History for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with's FREE daily email newsletter.